Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients (NEOpredict)
Brief Summary
The primary objective of this study is to determine the feasibility of four weeks of preoperative immunotherapy with Nivolumab, and Nivolumab plus Relatlimab in patients with early stage or locally advanced non-small cell lung cancer eligible for curative resection.
Intervention / Treatment
Study Design
Treatment
Randomized
Parallel Assignment
None (Open Label)
Arm Groups
Experimental: Nivolumab
Nivolumab 2 cycles, every two weeks (q2w)
Nivolumab 240 mg i.v. over 30 min
Experimental: Nivolumab/Relatlimab (80 mg)
Nivolumab/Relatlimab (80 mg) 2 cycles, every two weeks (q2w)
Nivolumab 240 mg i.v. over 30 min
Relatlimab 80 mg i.v. over 30 min (within 30 min of nivolumab)
Experimental: Nivolumab/Relatlimab (240 mg)
Nivolumab/Relatlimab (240 mg) 2 cycles, every two weeks (q2w)
Nivolumab 240 mg i.v. over 30 min
Relatlimab 240 mg i.v. over 30 min (within 30 min of nivolumab)
Eligibility Criteria
- Patients with histologically confirmed non-small cell lung cancer (NSCLC) eligible for anatomic resection (Clinical stages I B, II, and selected stage III A)
- Eastern Cooperative Oncology Group (ECOG) ≤ 1
- Sufficient pulmonary function to undergo curative lung cancer surgery
- Adequate hematological, hepatic and renal function parameters
- Sufficient cardiac left ventricular defined as left ventricular ejection fraction (LVEF) ≥ 50% documented either by echocardiography or multigated acquisition scan (MUGA)
- Patient able and willing to provide written informed consent and to comply with the study protocol and with the planned surgical procedures
- Active or history of autoimmune disease or immune deficiency
- Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration
- Subjects who have undergone organ transplant or allogeneic stem cell transplantation
- Uncontrolled or significant cardiovascular disease
- Patients with active neurological disease
- Active malignancy or a prior malignancy within the past 3 years
- Receipt of live attenuated vaccine within 30 days prior to the first dose of study medication
- Peripheral polyneuropathy NCI CTCAE Grade ≥ 2
- History of gastric perforation or fistulae in past 6 months
- Serious or non-healing wound, ulcer, or bone fracture within 28 days prior to enrollment
- The patient has undergone major surgery within 28 days prior to enrollment except staging mediastinoscopy, diagnostic Video Assisted Thoracoscopic Surgery (VATS) or implantation of a venous port-system
- Any other concurrent preoperative antineoplastic treatment including irradiation
- Pregnant/Breastfeeding women
- Subjects with history of severe toxicity or life-threatening toxicity (grade 3 or 4) related to prior immune therapy
- Prior treatment with lymphocyte-activation gene 3 (LAG-3) targeting Agent
- Previous treatment with Nivolumab or Relatlimab
Outcome Measures
Feasibility of four weeks of preoperative immunotherapy with Nivolumab, Nivolumab plus Relatlimab (80 mg), and Nivolumab plus Relatlimab (240 mg)
Within 43 days after first study medication
Estimation of pathological tumor response rate
Within 43 days after first study medication (day of surgery)
Estimation of curative (R0) resection rate
Within 43 days after first study medication (day of surgery)
Objective radiological response rate
Objective radiological response rate per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1
After 3, 6, 9 and 12 months post-surgery
Disease-free survival rate at 12 months
Assessment of disease-free survival rate at 12 months per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1
12 months
Overall survival rate at 12 months
12 months
Morbidity
Estimation of morbidity within 90 days after surgery
Within 90 days after surgery
Mortality
Estimation of mortality within 90 days after surgery
Within 90 days after surgery
Where is this study conducted?
We provide these clinical trial listings as a free service to the medical community based on public information sourced from ClinicalTrials.gov. We do not charge any fees for posting these types of trials. Please be aware that we are not responsible for the information displayed, as it is based on external public records.